Exelixis Price to Book Ratio 2006-2021 | EXEL

Historical price to book ratio values for Exelixis (EXEL) over the last 10 years. The current price to book ratio for Exelixis as of October 26, 2021 is 3.34.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Exelixis Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-27 21.30 3.28
2021-06-30 18.22 $6.49 2.81
2021-03-31 22.59 $6.10 3.70
2020-12-31 20.07 $6.03 3.33
2020-09-30 24.45 $5.99 4.08
2020-06-30 23.74 $5.94 4.00
2020-03-31 17.22 $5.72 3.01
2019-12-31 17.62 $5.53 3.19
2019-09-30 17.69 $5.28 3.35
2019-06-30 21.37 $4.92 4.35
2019-03-31 23.80 $4.59 5.18
2018-12-31 19.67 $4.29 4.58
2018-09-30 17.72 $3.06 5.78
2018-06-30 21.52 $2.60 8.27
2018-03-31 22.15 $2.26 9.81
2017-12-31 30.40 $0.96 31.60
2017-09-30 24.23 $0.81 30.01
2017-06-30 24.63 $0.51 48.71
2017-03-31 21.67 $0.41 52.89
2016-12-31 14.91 $0.31 48.39
2016-09-30 12.79 $0.11 114.30
2016-06-30 7.81 $-0.81 -9.66
2016-03-31 4.00 $-0.68 -5.87
2015-12-31 5.64 $-0.62 -9.13
2015-09-30 5.61 $-0.33 -17.09
2015-06-30 3.76 $-0.96 -3.92
2015-03-31 2.57 $-0.75 -3.43
2014-12-31 1.44 $-0.59 -2.46
2014-09-30 1.53 $-0.30 -5.10
2014-06-30 3.39 $0.02 204.22
2014-03-31 3.54 $0.37 9.64
2013-12-31 6.13 $0.36 17.08
2013-09-30 5.82 $0.72 8.07
2013-06-30 4.54 $1.07 4.26
2013-03-31 4.62 $1.39 3.33
2012-12-31 4.57 $1.61 2.83
2012-09-30 4.83 $1.86 2.60
2012-06-30 5.53 $0.67 8.31
2012-03-31 5.18 $0.89 5.81
2011-12-31 4.74 $0.67 7.08
2011-09-30 5.46 $0.02 232.34
2011-06-30 8.96 $-0.63 -14.12
2011-03-31 11.33 $-0.54 -21.07
2010-12-31 8.21 $-2.09 -3.93
2010-09-30 3.92 $-2.00 -1.96
2010-06-30 3.47 $-1.98 -1.76
2010-03-31 6.07 $-1.84 -3.31
2009-12-31 7.37 $-1.52 -4.86
2009-09-30 6.38 $-1.33 -4.80
2009-06-30 4.87 $-1.15 -4.23
2009-03-31 4.60 $-0.84 -5.51
2008-12-31 5.02 $-0.53 -9.49
2008-09-30 6.08 $-0.26 -23.82
2008-06-30 5.00 $0.06 89.93
2008-03-31 6.95 $0.38 18.33
2007-12-31 8.63 $0.69 12.54
2007-09-30 10.59 $0.81 13.05
2007-06-30 12.10 $0.20 59.58
2007-03-31 9.94 $0.39 25.32
2006-12-31 9.00 $0.55 16.44
2006-09-30 8.71 $-0.20 -42.57
2006-06-30 10.05 $0.01 858.97
2006-03-31 12.01 $0.17 70.56
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.824B $0.988B
Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ? (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86